BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 389 filers reported holding BIO-TECHNE CORP in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $919,485 | -17.6% | 12,833 | -19.1% | 0.01% | -12.5% |
Q1 2024 | $1,116,033 | -7.4% | 15,855 | +1.5% | 0.01% | -11.1% |
Q4 2023 | $1,205,548 | +12.2% | 15,624 | -1.0% | 0.01% | 0.0% |
Q3 2023 | $1,074,144 | -17.9% | 15,780 | -1.6% | 0.01% | -10.0% |
Q2 2023 | $1,308,447 | -6.5% | 16,029 | -15.0% | 0.01% | -16.7% |
Q1 2023 | $1,399,223 | -66.4% | 18,860 | -62.4% | 0.01% | -67.6% |
Q4 2022 | $4,161,322 | -6.7% | 50,209 | +219.6% | 0.04% | -9.8% |
Q3 2022 | $4,461,000 | -27.2% | 15,708 | -11.1% | 0.04% | -14.6% |
Q2 2022 | $6,126,000 | -24.4% | 17,673 | -5.6% | 0.05% | -2.0% |
Q1 2022 | $8,107,000 | -24.9% | 18,720 | -10.2% | 0.05% | -12.5% |
Q4 2021 | $10,788,000 | +42.9% | 20,855 | +33.8% | 0.06% | +24.4% |
Q3 2021 | $7,551,000 | +5.9% | 15,582 | -1.6% | 0.04% | +7.1% |
Q2 2021 | $7,132,000 | +14.9% | 15,841 | -2.5% | 0.04% | +2.4% |
Q1 2021 | $6,208,000 | +12.7% | 16,254 | -6.3% | 0.04% | +17.1% |
Q4 2020 | $5,507,000 | +6.2% | 17,344 | -17.1% | 0.04% | -7.9% |
Q3 2020 | $5,185,000 | -17.4% | 20,932 | -11.9% | 0.04% | -22.4% |
Q2 2020 | $6,277,000 | +55.5% | 23,770 | +11.7% | 0.05% | +19.5% |
Q1 2020 | $4,036,000 | -26.8% | 21,283 | -15.3% | 0.04% | 0.0% |
Q4 2019 | $5,515,000 | +43.6% | 25,123 | +28.0% | 0.04% | +32.3% |
Q3 2019 | $3,841,000 | -41.3% | 19,629 | -37.5% | 0.03% | -41.5% |
Q2 2019 | $6,547,000 | +33.2% | 31,402 | +26.9% | 0.05% | +32.5% |
Q1 2019 | $4,914,000 | +31.3% | 24,747 | -4.3% | 0.04% | +25.0% |
Q4 2018 | $3,742,000 | -42.3% | 25,857 | -18.6% | 0.03% | -23.8% |
Q3 2018 | $6,484,000 | +20.9% | 31,767 | -12.3% | 0.04% | +16.7% |
Q2 2018 | $5,362,000 | -52.2% | 36,241 | -51.2% | 0.04% | +33.3% |
Q1 2018 | $11,229,000 | +10.8% | 74,340 | -5.0% | 0.03% | +12.5% |
Q4 2017 | $10,139,000 | -19.7% | 78,261 | -25.1% | 0.02% | -20.0% |
Q3 2017 | $12,627,000 | +13.1% | 104,432 | +9.9% | 0.03% | 0.0% |
Q2 2017 | $11,168,000 | +14.2% | 95,037 | -1.2% | 0.03% | +11.1% |
Q1 2017 | $9,781,000 | -3.5% | 96,226 | -2.4% | 0.03% | -6.9% |
Q4 2016 | $10,137,000 | +23.5% | 98,581 | +31.5% | 0.03% | +11.5% |
Q3 2016 | $8,210,000 | -9.6% | 74,973 | -6.9% | 0.03% | -10.3% |
Q2 2016 | $9,085,000 | +2.5% | 80,567 | -14.1% | 0.03% | +3.6% |
Q1 2016 | $8,865,000 | -19.8% | 93,794 | -23.6% | 0.03% | -12.5% |
Q4 2015 | $11,055,000 | +23.2% | 122,841 | +26.6% | 0.03% | +14.3% |
Q3 2015 | $8,975,000 | -7.2% | 97,069 | -1.1% | 0.03% | +16.7% |
Q2 2015 | $9,669,000 | +10.6% | 98,190 | +12.6% | 0.02% | +14.3% |
Q1 2015 | $8,745,000 | +39.9% | 87,195 | +28.9% | 0.02% | +31.2% |
Q4 2014 | $6,253,000 | – | 67,671 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |